Pre-Test The Ever-Changing Therapeutic Landscape in Multiple Myeloma: Essential Guidance for Optimal Diagnosis and Management in Primary Care Pre-Test A 67-year-old White male presents with a 6-month history of lower back and hip pain. Laboratory results are as follows: Albumin 4.2 g/L, hemoglobin 10.3 g/dL, calcium 11.7 mg/dL, LDH 235 Iu/L, beta-2 macroglobulin 4.0 μg/mL, creatinine 1.2 mg/dL, creatinine clearance 43 mL/min, and bone marrow shows 42% clonal plasma cells IgG k. You determine he has MM. What is the preferred treatment? Autologous stem cell transplant and lenalidomide Lenalidomide, bortezomib, and dexamethasone Monotherapy with teclistamab Selinexor, pomalidomide, and dexamethasone Unsure A patient who exhibits a greater than or equal to 90% reduction in M protein levels after stem cell transplant is categorized as having a _____. Good response Partial response Very good partial response Complete response Unsure Which of the following agents can be used to treat patients with MM who have had four prior lines of therapy, according to the FDA label? Elotuzumab Isatuximab Liposomal doxorubicin Teclistamab Unsure How confident are you in your ability to implement multidisciplinary and collaborative care strategies for the optimal management of adverse events and treatment resistance in MM? Very confident Confident Somewhat confident Not very confident Not at all confident
